Loading candles…
Cipla Ltd, incorporated in 1935, operates in the pharmaceutical industry focusing on manufacturing, developing, and marketing a wide range of branded and generic formulations as well as active pharmaceutical ingredients (APIs). The company has a presence in India, South Africa, and the United States. Cipla's core offerings include products in therapeutic areas such as respiratory, anti-infectives, and cardiac care. It holds a leading position in the Indian pharmaceutical market (IPM). The company is engaged globally in providing affordable medicines across various treatment segments.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters | 13 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 23 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 30 Oct 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 25 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 13 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.